Strides Pharma Reports Strong Q3 FY24-25 Results Amid Score Revision

Strides Pharma Science has recently reported its financial results for the quarter ending December 2024, showcasing a very positive performance for Q3 FY24-25. However, the evaluation changes indicate a revision in its score, which has shifted to 24 from 33 over the past three months.
The financial data reveals significant growth in key metrics. Profit Before Tax less Other Income (PBT) reached Rs 110.66 crore, reflecting a remarkable year-on-year growth of 319%. Similarly, Profit After Tax (PAT) stood at Rs 89.87 crore, marking an 80.9% increase year-on-year. The company's ability to manage interest payments has also shown improvement, with the Operating Profit to Interest ratio peaking at 4.03 times, the highest in the last five quarters.

Additionally, Strides Pharma has demonstrated efficiency in inventory management, achieving an Inventory Turnover Ratio of 3.59 times, the highest in the last ten half-yearly periods. The Earnings per Share (EPS) has also reached a new high of Rs 9.54, indicating enhanced profitability for shareholders. Furthermore, the Debt-Equity Ratio has improved to its lowest at 1.02 times, suggesting a reduction in borrowing relative to equity capital.

For more insights, Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.